Hepatocellular carcinoma (HCC) is an aggressive and fatal cancer, comprising 90% of all liver cancer in adults worldwide. Diagnosis of HCC is often made when the disease is advanced and prognosis is poor. First-line systemic treatment options only provide a median overall survival (OS) of a few months, highlighting the need for more effective systemic therapy for patients with advanced or metastatic HCC.
The management of advanced HCC presents several challenges to oncologists, including tumor heterogeneity and compromised liver function due to cirrhosis and chronic viral infections. The development of biomarker-based treatment options is an important step towards individualizing the management of this heterogenous cancer. In this Clinical Toolkit, you will find clinical trial data on current and emerging therapies, recent treatment guidelines, and information on the role of alpha-fetoprotein (AFP) as a biomarker in the diagnosis and prognosis of HCC. Links to additional resources are also provided to ensure that clinicians remain up-to-date on the ever-evolving treatment landscape of HCC.